© 1998 American Heart Association, Inc.
Brief Review |
Development of Compartmental Models in Stable-Isotope Experiments
Application to Lipid Metabolism
From Laboratoire de Biochimie des Lipoprotéines, INSERM U498, Faculté de Médecine, Dijon, France.
Correspondence to Frédéric Pont, Laboratoire de Biochimie des Lipoprotéines, Hôpital du Bocage, BP 1542, 21034 Dijon, France.
Abstract—Kinetic experiments are of great importance in lipid research because they further the understanding of lipid metabolism in vivo and help to explain the physiopathology of lipid disorders in humans. At present, due to species specificity, no valid animal model can efficiently replace a study in humans to explore lipid metabolism, and the use of radioactive tracers is restricted in humans. Thus, stable-isotope tracer kinetic studies have become an important component of research programs to achieve in humans a quantitative understanding of the dynamics of metabolic processes in vivo. The aim of this review is to describe the practical aspects of compartmental model development in stable-isotope experiments. The recent development of computer hardware and modeling software has dramatically facilitated the task of the modeler in his or her calculations. In the current review, we show that the model may be considered an integral component of the experimental design and that model development must obey strict rules to provide a rigorous solution. The main difficulties of model development in tracer experiments, such as experiment design, model identifiability, data expression, comparison of models, or tracer recycling, are presented with extensive references. We have paid particular attention to kinetic modeling in stable-isotope experiments because they have shown the greatest development in recent years.
Key Words: compartmental models • stable isotopes • kinetics • lipids • lipoproteins
This article has been cited by other articles:
 |
|
 |
|
  B. Verges, E. Florentin, S. Baillot-Rudoni, J.-M. Petit, M. C. Brindisi, J.-P. Pais de Barros, L. Lagrost, P. Gambert, and L. Duvillard Rosuvastatin 20 mg restores normal HDL-apoA-I kinetics in type 2 diabetes J. Lipid Res., June 1, 2009; 50(6): 1209 - 1215. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Aravindhan, C. L. Webb, M. Jaye, A. Ghosh, R. N. Willette, N. J. DiNardo, and B. M. Jucker Assessing the effects of LXR agonists on cellular cholesterol handling: a stable isotope tracer study J. Lipid Res., June 1, 2006; 47(6): 1250 - 1260. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Verges, J. M. Petit, L. Duvillard, G. Dautin, E. Florentin, F. Galland, and P. Gambert Adiponectin Is an Important Determinant of ApoA-I Catabolism Arterioscler Thromb Vasc Biol, June 1, 2006; 26(6): 1364 - 1369. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ouguerram, M. Chetiveaux, Y. Zair, P. Costet, M. Abifadel, M. Varret, C. Boileau, T. Magot, and M. Krempf Apolipoprotein B100 Metabolism in Autosomal-Dominant Hypercholesterolemia Related to Mutations in PCSK9 Arterioscler Thromb Vasc Biol, August 1, 2004; 24(8): 1448 - 1453. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sabatier, F. Pont, M. J. Arnaud, and J. R. Turnlund A compartmental model of magnesium metabolism in healthy men based on two stable isotope tracers Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2003; 285(3): R656 - R663. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Ouguerram, T. Magot, Y. Zair, J. S. Marchini, B. Charbonnel, H. Laouenan, and M. Krempf Effect of Atorvastatin on Apolipoprotein B100 Containing Lipoprotein Metabolism in Type-2 Diabetes J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 332 - 337. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Pont, L. Duvillard, E. Florentin, P. Gambert, and B. Verges Early Kinetic Abnormalities of ApoB-Containing Lipoproteins in Insulin-Resistant Women With Abdominal Obesity Arterioscler Thromb Vasc Biol, October 1, 2002; 22(10): 1726 - 1732. [Abstract] [Full Text] [PDF]
|
|